| Product Unit Size | Cost | Quantity | Stock |
|---|
Tirzepatide is a dual GLP-1/GIP receptor co-agonist. It has been shown to stimulate catabolism of branched-chain amino acids and branched-chain keto acids in thermogenic brown adipose tissue in mice. It has demonstrated superior glycemic control compared with GLP-1R agonism and improved insulin sensitivity.
This product is intended for laboratory and research use only, not for drug or human use.
| Cas No. | 2023788-19-2 |
|---|---|
| Purity | ≥98% |
| Formula | C225H347N47O69 |
| Formula Wt. | 4813 |
| IUPAC Name | [(2S)-2-[[(2S)-1-[(2S)-1-[(2S)-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[2-[[2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-2-methyl-propanoyl]amino]-4-carboxy-butanoyl]amino]acetyl]amino]-3-hydroxy-butanoyl]amino]-3-phenyl-propanoyl]amino]-3-hydroxy-butanoyl]amino]-3-hydroxy-propanoyl]amino]-3-carboxy-propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxy-propanoyl]amino]-3-methyl-pentanoyl]amino]-2-methyl-propanoyl]amino]-4-methyl-pentanoyl]amino]-3-carboxy-propanoyl]amino]hexanoyl]amino]-3-methyl-pentanoyl]amino]propanoyl]amino]-5-oxo-pentanoyl]amino]-6-[[2-[2-[2-[[2-[2-[2-[[(4R)-4-carboxy-4-(19-carboxynonadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]hexanoyl]amino]propanoyl]amino]-3-phenyl-propanoyl]amino]-3-methyl-butanoyl]amino]-5-oxo-pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methyl-pentanoyl]amino]-3-methyl-pentanoyl]amino]propanoyl]amino]acetyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-hydroxy-propanoyl]amino]-3-hydroxy-propanoyl]amino]acetyl]amino]propanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-3-hydroxy-propanoyl] |
| Synonym | LY3298176 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet |
|---|
Sinha R, Papamargaritis D, Sargeant J, et al. Efficacy and safety of tirzepatide in type 2 diabetes and obesity management. J Obes Metab Syndr. 2023 Mar 30;32(1):25-45. PMID: 36750526
Sams R, Zhang G, He W, er al. Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue. Mol Metab. 2022 Oct;64:101550. PMID: 35921984
Samms R, Christe M, Collins K, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest. 2021 Jun 15;131(12):e146353. PMID: 34003802